162 related articles for article (PubMed ID: 2633887)
1. Community-based treatment of onchocerciasis with ivermectin: acceptability and early adverse reactions.
Pacque MC; Dukuly Z; Greene BM; Munoz B; Keyvan-Larijani E; Williams PN; Taylor HR
Bull World Health Organ; 1989; 67(6):721-30. PubMed ID: 2633887
[TBL] [Abstract][Full Text] [Related]
2. Safety of and compliance with community-based ivermectin therapy.
Pacqué M; Muñoz B; Greene BM; White AT; Dukuly Z; Taylor HR
Lancet; 1990 Jun; 335(8702):1377-80. PubMed ID: 1971669
[TBL] [Abstract][Full Text] [Related]
3. Community-based treatment of onchocerciasis with ivermectin: safety, efficacy, and acceptability of yearly treatment.
Pacqué M; Muñoz B; Greene BM; Taylor HR
J Infect Dis; 1991 Feb; 163(2):381-5. PubMed ID: 1988522
[TBL] [Abstract][Full Text] [Related]
4. Reduction in the prevalence and intensity of infection in Onchocerca volvulus microfilariae according to ethnicity and community after 8 years of ivermectin treatment on the island of Bioko, Equatorial Guinea.
Mas J; Ascaso C; Escaramis G; Abellana R; Duran E; Sima A; Sánchez MJ; Nkogo PR; Nguema R; Untoria MD; Echeverria MA; Ardevol MM; de Jiménez Anta MT
Trop Med Int Health; 2006 Jul; 11(7):1082-91. PubMed ID: 16827709
[TBL] [Abstract][Full Text] [Related]
5. Serious reactions after mass treatment of onchocerciasis with ivermectin in an area endemic for Loa loa infection.
Gardon J; Gardon-Wendel N; Demanga-Ngangue ; Kamgno J; Chippaux JP; Boussinesq M
Lancet; 1997 Jul; 350(9070):18-22. PubMed ID: 9217715
[TBL] [Abstract][Full Text] [Related]
6. Single dose moxidectin versus ivermectin for Onchocerca volvulus infection in Ghana, Liberia, and the Democratic Republic of the Congo: a randomised, controlled, double-blind phase 3 trial.
Opoku NO; Bakajika DK; Kanza EM; Howard H; Mambandu GL; Nyathirombo A; Nigo MM; Kasonia K; Masembe SL; Mumbere M; Kataliko K; Larbelee JP; Kpawor M; Bolay KM; Bolay F; Asare S; Attah SK; Olipoh G; Vaillant M; Halleux CM; Kuesel AC
Lancet; 2018 Oct; 392(10154):1207-1216. PubMed ID: 29361335
[TBL] [Abstract][Full Text] [Related]
7. Chemokines in onchocerciasis patients after a single dose of ivermectin.
Fendt J; Hamm DM; Banla M; Schulz-Key H; Wolf H; Helling-Giese G; Heuschkel C; Soboslay PT
Clin Exp Immunol; 2005 Nov; 142(2):318-26. PubMed ID: 16232219
[TBL] [Abstract][Full Text] [Related]
8. A Test-and-Not-Treat Strategy for Onchocerciasis in Loa loa-Endemic Areas.
Kamgno J; Pion SD; Chesnais CB; Bakalar MH; D'Ambrosio MV; Mackenzie CD; Nana-Djeunga HC; Gounoue-Kamkumo R; Njitchouang GR; Nwane P; Tchatchueng-Mbouga JB; Wanji S; Stolk WA; Fletcher DA; Klion AD; Nutman TB; Boussinesq M
N Engl J Med; 2017 Nov; 377(21):2044-2052. PubMed ID: 29116890
[TBL] [Abstract][Full Text] [Related]
9. Onchocerca volvulus microfilariae in the anterior chambers of the eye and ocular adverse events after a single dose of 8 mg moxidectin or 150 µg/kg ivermectin: results of a randomized double-blind Phase 3 trial in the Democratic Republic of the Congo, Ghana and Liberia.
Kanza EM; Nyathirombo A; Larbelee JP; Opoku NO; Bakajika DK; Howard HM; Mambandu GL; Nigo MM; Wonyarossi DU; Ngave F; Kennedy KK; Kataliko K; Bolay KM; Attah SK; Olipoh G; Asare S; Mumbere M; Vaillant M; Halleux CM; Kuesel AC
Parasit Vectors; 2024 Mar; 17(1):137. PubMed ID: 38491528
[TBL] [Abstract][Full Text] [Related]
10. Adverse reactions after large-scale treatment of onchocerciasis with ivermectin: combined results from eight community trials.
De Sole G; Remme J; Awadzi K; Accorsi S; Alley ES; Ba O; Dadzie KY; Giese J; Karam M; Keita FM
Bull World Health Organ; 1989; 67(6):707-19. PubMed ID: 2633886
[TBL] [Abstract][Full Text] [Related]
11. Ivermectin: reduction in prevalence and infection intensity of Onchocerca volvulus following biannual treatments in five Guatemalan communities.
Collins RC; Gonzales-Peralta C; Castro J; Zea-Flores G; Cupp MS; Richards FO; Cupp EW
Am J Trop Med Hyg; 1992 Aug; 47(2):156-69. PubMed ID: 1503185
[TBL] [Abstract][Full Text] [Related]
12. The chemotherapy of onchocerciasis. XIII. Studies with ivermectin in onchocerciasis patients in northern Ghana, a region with long lasting vector control.
Awadzi K; Dadzie KY; Kläger S; Gilles HM
Trop Med Parasitol; 1989 Sep; 40(3):361-6. PubMed ID: 2694315
[TBL] [Abstract][Full Text] [Related]
13. A community-based cross-sectional study of the epidemiology of onchocerciasis in unmapped villages for community directed treatment with ivermectin in Jimma Zone, southwestern Ethiopia.
Dana D; Debalke S; Mekonnen Z; Kassahun W; Suleman S; Getahun K; Yewhalaw D
BMC Public Health; 2015 Jul; 15():595. PubMed ID: 26130117
[TBL] [Abstract][Full Text] [Related]
14. A community trial of ivermectin in the onchocerciasis focus of Asubende, Ghana. I. Effect on the microfilarial reservoir and the transmission of Onchocerca volvulus.
Remme J; Baker RH; De Sole G; Dadzie KY; Walsh JF; Adams MA; Alley ES; Avissey HS
Trop Med Parasitol; 1989 Sep; 40(3):367-74. PubMed ID: 2617046
[TBL] [Abstract][Full Text] [Related]
15. [Secondary effects of the treatment of hypermicrofilaremic loiasis using ivermectin].
Ducorps M; Gardon-Wendel N; Ranque S; Ndong W; Boussinesq M; Gardon J; Schneider D; Chippaux JP
Bull Soc Pathol Exot; 1995; 88(3):105-12. PubMed ID: 8555762
[TBL] [Abstract][Full Text] [Related]
16. Effect of semiannual treatments of ivermectin on the prevalence and intensity of Onchocerca volvulus skin infection, ocular lesions, and infectivity of Simulium ochraceum populations in southern Mexico.
Rodriguez-Perez MA; Rodriguez MH; Margeli-Perez HM; Rivas-Alcala AR
Am J Trop Med Hyg; 1995 May; 52(5):429-34. PubMed ID: 7771609
[TBL] [Abstract][Full Text] [Related]
17. Implications for annual retesting after a test-and-not-treat strategy for onchocerciasis elimination in areas co-endemic with Loa loa infection: an observational cohort study.
Pion SD; Nana-Djeunga H; Niamsi-Emalio Y; Chesnais CB; Deléglise H; Mackenzie C; Stolk W; Fletcher DA; Klion AD; Nutman TB; Boussinesq M; Kamgno J
Lancet Infect Dis; 2020 Jan; 20(1):102-109. PubMed ID: 31676244
[TBL] [Abstract][Full Text] [Related]
18. The chemotherapy of onchocerciasis X. An assessment of four single dose treatment regimes of MK-933 (ivermectin) in human onchocerciasis.
Awadzi K; Dadzie KY; Shulz-Key H; Haddock DR; Gilles HM; Aziz MA
Ann Trop Med Parasitol; 1985 Feb; 79(1):63-78. PubMed ID: 3838638
[TBL] [Abstract][Full Text] [Related]
19. Effect of ivermectin on the vertical distribution of Onchocerca volvulus microfilariae in the skin.
Jürgens S; Schulz-Key H
Trop Med Parasitol; 1990 Jun; 41(2):165-8. PubMed ID: 2382096
[TBL] [Abstract][Full Text] [Related]
20. Adverse reactions to ivermectin treatment in Simulium neavei-transmitted onchocerciasis.
Kipp W; Bamhuhiiga J; Rubaale T; Büttner DW
Am J Trop Med Hyg; 2003 Dec; 69(6):621-3. PubMed ID: 14740878
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
